

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



思路迪医药

3D Medicines

3D Medicines Inc.

思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

CHANGE OF PROCESS AGENT AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

CHANGE OF AGENT FOR THE SERVICE OF PROCESS AND NOTICES

The board of directors of the Company (the “**Board**”) is pleased to announce that Ms. Leung Ching Ching has been appointed in replacement of Ms. Li Ching Yi as the agent for the acceptance of service of process and notices (the “**Process Agent**”) in Hong Kong on behalf of the Company under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from August 4, 2026.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Board further announces that the Company’s principal place of business in Hong Kong will be changed to 16/F, Wing On Centre, 111 Connaught Road Central, Hong Kong, with effect from August 4, 2026.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, August 4, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.